---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-017116"
form_type: "8-K"
ticker: "AURX"
cik: "0001091596"
company_name: "Nuo Therapeutics, Inc."
filed_at: "2026-05-14T21:11:29+00:00"
generated_at: "2026-05-14T21:12:35.177578+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuo Therapeutics Q1 revenues up 169% YoY to $1.3M; operating loss narrows

## Summary
- Total revenue $1.3M, including $1.22M product sales, up 169% YoY and 20% sequential.
- Aurix branded product revenue rose over 30% sequentially versus Q4 2025.
- Net operating loss improved to $446,000 from $745,000 in Q1 2025.
- Entered $1.0M Loan and Security Agreement to fund growth as company approaches breakeven.
- CEO cites strong Aurix demand and favorable Medicare reimbursement shift for autologous PRP.

## SEC filing metadata
- accession: 0001437749-26-017116
- form_type: 8-K
- ticker: AURX
- cik: 0001091596
- company_name: Nuo Therapeutics, Inc.
- filed_at: 2026-05-14T21:11:29+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1091596/000143774926017116/0001437749-26-017116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1091596/000143774926017116/aurx20260514_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-017116
- JSON: https://secwatch.observer/filing/0001437749-26-017116.json
- Plain text: https://secwatch.observer/filing/0001437749-26-017116.txt

## Key facts
- Earnings Releases
  Nuo Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue approximately $1.3 million.
  - Period: the first quarter ended March 31, 2026
  - Revenue: approximately $1.3 million
  - Result: reported results
  source text: results for the first quarter ended March 31, 2026 and provided an operational and business update. First Quarter 2026 Financial Summary ● Total revenues of approximately $1.3 million (including approximately $1,224,000 of product revenues) increased 169% over the 2025 first quarter and 20% over last year’s fourth quarter ● Aurix branded product revenues were
  evidence_url: https://www.sec.gov/Archives/edgar/data/1091596/000143774926017116/0001437749-26-017116-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.